Portal de Periódicos da CAPES

Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World”? A Systematic Review

2023; Elsevier BV; Volume: 7; Issue: 1 Linguagem: Inglês

10.1016/j.euo.2023.05.002

2588-9311

Joanna Dodkins, Julie Nossiter, Adrian Cook, H. Payne, Noel W. Clarke, Jan van der Meulen, Ajay Aggarwal,

Radiopharmaceutical Chemistry and Applications

Since 2015 there have been major advances in the management of primary metastatic hormone-sensitive prostate cancer (mHSPC) following the publication of key clinical trials that demonstrated significant clinical benefits with docetaxel chemotherapy or novel hormone therapy (NHT) in addition to androgen deprivation therapy (ADT). Despite these advances, there is evidence to show that these treatments are not being utilised for mHSPC in clinical practice.